Skip to content

Study · Not a test of the peptide alone · 2017

4 results

Rates of hypoglycaemia are lower in patients treated with insulin degludec/liraglutide (IDegLira) than with IDeg or insulin glargine, regardless of the hypoglycaemia definition used.

Norwood P, Chen R, Jaeckel E, Lingvay I, Jarlov H, Lehmann L, Heller S

Diabetes, obesity & metabolism10 Jul 2017Cited by 3 (Europe PMC)

PMID28417535 (opens in a new tab)PMCIDPMC5655847 (opens in a new tab)DOI10.1111/dom.12972 (opens in a new tab)PepBankPUB-28417535
Read at sourcePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

  1. 01HumanNot a test of Liraglutide aloneRandomized controlled trialSafety outcome

    In adults with type 2 diabetes, hypoglycaemia rates were consistently lower with IDegLira (insulin degludec plus liraglutide) than with insulin degludec and insulin glargine U100 under all alternative hypoglycaemia definitions.

    In plain wordsIn adults with type 2 diabetes, an insulin-plus-liraglutide combination caused fewer low blood sugar events than insulin alone, however low blood sugar was defined.

    Peptide
    Liraglutide
    Outcome
    DecreaseHypoglycaemia rates under alternative definitions
    Study

    n: not reported in source

    Comparator
    Insulin degludec or insulin glargine U100
    Outcome group
    Adverse events · Metabolic and weight

    Source sentences

    Summary
    Although hypoglycaemia rates differed according to the alternative hypoglycaemia definitions, rates were consistently lower with IDegLira vs insulin degludec (IDeg) and IGlar U100.
    1 context sentence
    Summary · context
    Post hoc analyses of the DUAL I (patients uncontrolled on oral antidiabetic drugs) and DUAL V (patients uncontrolled on insulin glargine (IGlar) U100) trials were carried out using different definitions of hypoglycaemia and according to whether treatments were administered in the morning or afternoon.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  2. 02HumanNot a test of Liraglutide aloneRandomized controlled trialSafety outcome

    In adults with type 2 diabetes, confirmed and nocturnal-confirmed hypoglycaemia rates were lower with IDegLira than with insulin degludec and insulin glargine U100, irrespective of dosing time.

    In plain wordsIn adults with type 2 diabetes, the insulin-plus-liraglutide combination caused fewer confirmed and night-time low blood sugar events than insulin alone, whatever the dosing time.

    Peptide
    Liraglutide
    Outcome
    DecreaseConfirmed and nocturnal-confirmed hypoglycaemia by dosing time
    Study

    n: not reported in source

    Comparator
    Insulin degludec or insulin glargine U100
    Outcome group
    Adverse events · Metabolic and weight

    Source sentences

    Summary
    confirmed and nocturnal-confirmed hypoglycaemia rates were lower for IDegLira vs IDeg and IGlar U100, irrespective of dosing time.
    1 context sentence
    Summary · context
    Post hoc analyses of the DUAL I (patients uncontrolled on oral antidiabetic drugs) and DUAL V (patients uncontrolled on insulin glargine (IGlar) U100) trials were carried out using different definitions of hypoglycaemia and according to whether treatments were administered in the morning or afternoon.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  3. 03HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, glycated haemoglobin concentrations were lower with IDegLira than with the basal insulin comparators at end of treatment.

    In plain wordsIn adults with type 2 diabetes, average blood sugar was lower with the insulin-plus-liraglutide combination than with insulin alone at the end of treatment.

    Peptide
    Liraglutide
    Outcome
    DecreaseHbA1c at end of treatment
    Study

    n: not reported in source

    Comparator
    Insulin degludec or insulin glargine U100
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    Despite glycated haemoglobin concentrations being lower with IDegLira at end of treatment
    1 context sentence
    Summary · context
    Post hoc analyses of the DUAL I (patients uncontrolled on oral antidiabetic drugs) and DUAL V (patients uncontrolled on insulin glargine (IGlar) U100) trials were carried out using different definitions of hypoglycaemia and according to whether treatments were administered in the morning or afternoon.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  4. 04HumanNot a test of Liraglutide aloneRandomized controlled trialSafety outcome

    In adults with type 2 diabetes, the choice of hypoglycaemia definition did not significantly change the treatment difference between IDegLira and the comparators when assessed by baseline age, gender and BMI.

    In plain wordsIn adults with type 2 diabetes, the way low blood sugar was defined did not change the treatment difference across age, gender or BMI groups.

    Peptide
    Liraglutide
    Outcome
    No significant changeHypoglycaemia treatment difference by age, gender and BMI
    Study

    n: not reported in source

    Comparator
    Insulin degludec or insulin glargine U100
    Outcome group
    Adverse events · Metabolic and weight

    Source sentences

    Summary
    The definitions of confirmed and ADA-documented symptomatic hypoglycaemia did not have a significant effect on the treatment difference between IDegLira and IDeg, liraglutide or IGlar U100 when further assessed by baseline age, gender and BMI.
    1 context sentence
    Summary · context
    Post hoc analyses of the DUAL I (patients uncontrolled on oral antidiabetic drugs) and DUAL V (patients uncontrolled on insulin glargine (IGlar) U100) trials were carried out using different definitions of hypoglycaemia and according to whether treatments were administered in the morning or afternoon.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 2 completed · 2 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT01952145

A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide Versus Insulin Glargine in Subjects With Type 2 Diabetes Mellitus

Novo Nordisk A/Sn = 55720 Sept 2013 to 4 Nov 2014

Diabetes · Diabetes Mellitus, Type 2

Trial pageClinicalTrials.govUpdated 3 Jan 2019
CompletedPhase 3Results postedNCT01336023

Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 Diabetes

Novo Nordisk A/Sn = 1,66323 May 2011 to 22 Nov 2012

Diabetes · Diabetes Mellitus, Type 2

Trial pageClinicalTrials.govUpdated 19 Feb 2018

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.